Industryweek 3953 Accenture Biopharmaceutical Industry Study 2012

Pharmaceutical Industry: Life Beyond the Patent Cliff [INFOGRAPHIC]

March 15, 2013
A new Accenture study shows that the negative impact from sales lost to patent expiration peaked in 2012 and will lessen.

Accenture discovered some positive trends after analyzing the financial performance of the 16 largest, pure biopharmaceutical companies over the past 7 years.

From 2013 on their findings show:

The negative impact from sales lost to patent expiration peaked in 2012 and will lessen.

The ratio of revenue from the pipeline and current portfolio compared to sales lost from patent expiry will improve.

Select companies are showing notably improved performance.

"Investors are looking beyond the patent crisis and valuing companies that have clearly articulated a path to sustainable growth and are making substantial strategic and operational changes to achieve their growth objectives," the company said. 

Popular Sponsored Recommendations

Shifting Your Business from Products to Service-Based Business Models: Generating Predictable Revenues

Oct. 27, 2023
Executive summary on a recent IndustryWeek-hosted webinar sponsored by SAP

Why DataOps may be the key to unlocking the full potential of digital transformation

Nov. 3, 2023
Read the 2023 market survey conducted by IndustryWeek

How to Build Zero-Cost On-Site Solar and Storage Projects

Nov. 25, 2023
The Inflation Reduction Act offers tax credits, incentives, and financing that enable no-cost projects. In Enel’s eBook, discover the critical role that incentives play in your...

Discover How an Eye Tracking Study Improves Training Procedures

Oct. 29, 2023
Did you know that your training processes can be streamlined by visualizing and analyzing key skills within your employee base? Find out how we use eye tracking to capture advanced...

Voice your opinion!

To join the conversation, and become an exclusive member of IndustryWeek, create an account today!